Filter News
Area of Research
- (-) Nuclear Science and Technology (7)
- (-) Supercomputing (8)
- Advanced Manufacturing (1)
- Biology and Environment (6)
- Clean Energy (8)
- Energy Frontier Research Centers (1)
- Fuel Cycle Science and Technology (1)
- Fusion and Fission (1)
- Isotopes (1)
- Materials (13)
- Materials for Computing (1)
- National Security (1)
- Neutron Science (7)
News Topics
- (-) Advanced Reactors (2)
- (-) Biomedical (3)
- (-) Climate Change (1)
- (-) Grid (1)
- (-) Nanotechnology (3)
- (-) Nuclear Energy (6)
- 3-D Printing/Advanced Manufacturing (3)
- Artificial Intelligence (2)
- Bioenergy (3)
- Biology (1)
- Chemical Sciences (1)
- Computer Science (12)
- Coronavirus (3)
- Decarbonization (1)
- Energy Storage (1)
- Environment (3)
- Fusion (1)
- High-Performance Computing (1)
- Isotopes (3)
- Machine Learning (1)
- Materials (2)
- Materials Science (3)
- Microscopy (2)
- Molten Salt (1)
- National Security (1)
- Neutron Science (5)
- Physics (2)
- Quantum Science (4)
- Space Exploration (1)
- Summit (7)
- Sustainable Energy (3)
- Transformational Challenge Reactor (1)
- Transportation (2)
Media Contacts
OAK RIDGE, Tenn., Feb. 19, 2020 — The U.S. Department of Energy’s Oak Ridge National Laboratory and the Tennessee Valley Authority have signed a memorandum of understanding to evaluate a new generation of flexible, cost-effective advanced nuclear reactors.
The Department of Energy’s Oak Ridge National Laboratory is collaborating with industry on six new projects focused on advancing commercial nuclear energy technologies that offer potential improvements to current nuclear reactors and move new reactor designs closer to deployment.
The United Kingdom’s National Nuclear Laboratory and the U.S. Department of Energy’s Oak Ridge National Laboratory have agreed to cooperate on a wide range of nuclear energy research and development efforts that leverage both organizations’ unique expertise and capabilities.
The Department of Energy’s Oak Ridge National Laboratory is now producing actinium-227 (Ac-227) to meet projected demand for a highly effective cancer drug through a 10-year contract between the U.S. DOE Isotope Program and Bayer.